Recent progress in advanced glycation and diabetic vascular disease: Role of advanced glycation end product receptors

Diabetes

Volumn 45, Issue 3 SUPPL., 1996, Pages

  Vlassara, Helen ^a   Bucala, Richard ^a  

^a PICOWER INST FOR MEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE RECEPTOR; COLLAGEN TYPE 4; FIBRONECTIN; GLYCOSYLATED PROTEIN; GROWTH FACTOR; LAMININ; MESSENGER RNA;

ATHEROSCLEROSIS; BASEMENT MEMBRANE; COMPLEX FORMATION; CONFERENCE PAPER; CONNECTIVE TISSUE; DIABETES MELLITUS; DIABETIC ANGIOPATHY; EXTRACELLULAR MATRIX; GLOMERULOSCLEROSIS; HUMAN; KIDNEY FAILURE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN GLYCOSYLATION; PROTEIN MODIFICATION; PROTEIN SECRETION;

ANIMALS; DIABETIC ANGIOPATHIES; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; RECEPTORS, IMMUNOLOGIC;

EID: 0029882358     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diab.45.3.s65     Document Type: Article

References (12)

1. Brownlee M, Cerami A, Vlassara, H: Advanced glycosylation endproducts in tissue and the biochemical basis of diabetic complications. N Engl J Med 318:1315-1321, 1988
2. Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Friedman EA, Cerami A, Vlassara H: Advanced glycosylation endproducts in patients with diabetic nephropathy. N Engl J Med 325:830-842, 1991
3. Vlassara H, Brownlee M, Cerami A: High-affinity receptor-mediated uptake and degradation of glucose-modified proteins: a potential mechanism for the removal of senescent macromolecules. Proc Natl Acad Sci USA 82:5588-5592, 1985
4. Vlassara H, Brownlee M, Cerami A: Novel macrophage receptor for glucose-modified proteins is distinct from previously described scavenger receptors. J Exp Med 164:1301-1309, 1986
5. Vlassara H, Brownlee M, Manogue KR, Dinarello C, Pasagian A: Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodelling. Science 240:1546-1548, 1988
6. Kirstein M, Brett J, Radoff S, Stern D, Vlassara H: Advanced glycosylation endproducts selectively induce monocyte migration across intact endothelial cell monolayers, and elaboration of growth factors: role in aging and diabetic vasculopathy. Proc Natl Acad Sci USA 87:9010-9014, 1990
7. Kirstein M, Aston C, Hintz R, Vlassara H: Receptor-specific induction of insulin-like growth factor I (IGF-I) in human monocytes by advanced glycosylation endproduct-modified proteins. J Clin Invest 90:439-446, 1992
8. Skolnik EY, Yang Z, Makita Z, Radoff S, Kirstein M, Vlassara H: Human and rat mesangial cell receptors for glucose-modified proteins: potential role in kidney tissue remodelling and diabetic nephropathy. J Exp Med 174:931-939, 1991
9. Doi T, Vlassara H, Kirstein M, Yamada Y, Striker GE, Striker LJ: Receptor-specific increased mesangial cell extracellular matrix production is mediated by PDGF. Proc Natl Acad Sci USA 89:2873-2877, 1992
10. Vlassara H, Fuh H, Makita Z, Krungkrai S, Cerami A, Bucala R: Exogenous advanced glycosylation endproducts induce complex vascular dysfunction in normal animals; a model for diabetic and aging complications. Proc Natl Acad Sci USA 89:12013-12047, 1992
11. Yang CW, Vlassara H, Peten EP, He CJ, Striker GE, Striker LJ: Advanced glycosylation endproducts upregulate gene expression found in diabetic glomerular disease. Proc Natl Acad Sci USA 90:9436-9440, 1994
12. Vlassara H, Striker LJ, Teichberg S, Fuh H, Li YM, Steffes M: Advanced glycation endproducts induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci USA 91:11704-11708, 1994